Explanipedia

Tumor sink effect on melanin-ligand [131I]ICF01012 in melanoma and its implications for targeted radionuclide therapy Open

E. Jouberton, Sophie Besse, Tommy Billoux, Philippe Auzeloux, Sébastien Schmitt , et al. · 2025

These findings suggest that tumor burden impacts [¹³¹I]ICF01012 distribution in non-target organs, with potential clinical implications for dosimetry and toxicity mitigation in radiopharmaceutical therapy for metastatic melanoma…

[99mTc]Tc-NTP 15 − 5, a new proteoglycan tracer for functional imaging of joint cartilage: phase I (CARSPECT) Open

M. Chanchou, Émilie Thivat, Sylvain Mathieu, Sophie Lévesque, N.C.F. van Sas , et al. · 2025

Clinicaltrials.gov: NCT04481230. https://clinicaltrials.gov/ct2/show/NCT04481230 . Registration date: November, 12th, 2020.

P-041 Impact of ionizing radiation on human spermatozoa integrity Open

Hanae Pons‐Rejraji, Oriana Carcy, N.C.F. van Sas, N Billoux, E. Jouberton , et al. · 2025

Study question Do ionizing radiations affect human sperm integrity? If so, at what dose? Summary answer In vitro exposure of human ejaculated spermatozoa significantly reduces vitality, motility, and chromatin integrity without causing DNA…

Large-vessel involvement in ANCA-associated vasculitis: A multicenter case-control study Open

V. Monghal, Xavier Puéchal, P. Smets, Frédéric Vandergheynst, Marc Michel , et al. · 2024

97P Tumor-associated macrophages: A tool for the treatment of chondrosarcoma Open

Rohan Quoniou, Caroline Peyrode, Emmanuel Moreau, Emmanuel Chautard, F. Cachin , et al. · 2024

Chondrosarcoma, or malignant cartilage tumor, is the second most common bone cancer after osteosarcoma. Chemo- and radio-resistant due to its poor vascularization and the chondrogenic nature of its extracellular matrix (ECM), its managemen…

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence Open

Arnaud Dieudonné, Clément Bailly, F. Cachin, Agathe Edet‐Sanson, Françoise Kraeber‐Bodéré , et al. · 2023

International audience

Imaging quality of an artificial intelligence denoising algorithm: validation in 68Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer Open

Charles Margail, C. Merlin, Tommy Billoux, Maxence Wallaert, H. Otman , et al. · 2023

Background 68 Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed th…

Imaging quality of an artificial intelligence denoising algorithm: validation in 68Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer Open

Charles Margail, C. Merlin, Tommy Billoux, Maxence Wallaert, H. Otman , et al. · 2023

Background 68 Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an Artificial Intelligence-based denoising algorithm. To address this issue, we analyzed th…

Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker Open

Eve Faugeras, Lauren Véronèse, G. Jeannin, Henri Janicot, Sébastien Bailly , et al. · 2022

Telomere length appears to correlate with survival in early non-small-cell lung cancer (NSCLC), but the prognostic impact of telomere status in advanced NSCLC remains undetermined. Our purpose was to evaluate telomere parameters as prognos…

Assessment of 99mTc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT) Open

Émilie Thivat, M. Chanchou, Sylvain Mathieu, Sophie Lévesque, Tommy Billoux , et al. · 2022

Background 99m Tc-NTP 15-5 is a SPECT radiotracer targeting proteoglycans (PG), components of the cartilaginous extracellular matrix. Imaging of PGs would be useful for the early detection of cartilage disorders (osteoarthritis, arthritis …

Delayed [18F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis Open

H. Otman, J. Farce, Pierre Meneret, Xavier Palard-Novello, Pierre‐Jean Le Reste , et al. · 2022

Purpose Differentiating brain metastasis recurrence from radiation necrosis can be challenging during MRI follow-up after stereotactic radiotherapy. [ 18 F]-FDG is the most available PET tracer, but standard images performed 30 to 60 minut…

99mTc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model Open

Arnaud Briat, C. Jacques, Mélodie Malige, L. Sudre, Geoffroy Nourissat , et al. · 2022

Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol Open

Émilie Thivat, Jacques Rouanet, Philippe Auzeloux, N.C.F. van Sas, E. Jouberton , et al. · 2022

Background Benzamide-based radioligands targeting melanin were first developed for imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy (TRT). [ 131 I]ICF01012 presents a highly favorable pharmacokinetics pr…

Untargeted 2D NMR Metabolomics of [13C-methyl]Methionine-Labeled Tumor Models Reveals the Non-DNA Methylome and Provides Clues to Methyl Metabolism Shift during Tumor Progression Open

Daniel Morvan, F. Cachin · 2022

For more than a decade, DNA and histone methylations have been the focus of extensive work, although their relationship with methyl group metabolism was overlooked. Recently, it has emerged that epigenetic methylations are influenced by me…

Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment Open

Anthime Flaus, Vincent Habouzit, Nicolas De Leiris, Jean‐Philippe Vuillez, M.‐T. Leccia , et al. · 2022

(1) Background: As outcome of patients with metastatic melanoma treated with anti-PD1 immunotherapy can vary in success, predictors are needed. We aimed to predict at the patients’ levels, overall survival (OS) and progression-free surviva…

Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs. Open

E. Jouberton, Aurélien Voissière, Frédérique Penault‐Llorca, F. Cachin, Élisabeth Miot-Noirault · 2022

An increasing number of studies concerning solid cancers, including prostate cancer, are tending to demonstrate the predominant role of the interactions of tumor cells with their microenvironment, and underlining the relevance of therapeut…

Interest and Limits of [18F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy Open

E. Jouberton, Sébastien Schmitt, Aurélie Maisonial‐Besset, Emmanuel Chautard, Frédérique Penault‐Llorca , et al. · 2021

One of the current challenges in oncology is to develop imaging tools to early detect the response to conventional chemotherapy and adjust treatment strategies when necessary. Several studies evaluating PET imaging with 2-deoxy-2-[ 18 F]fl…

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy Open

Anthime Flaus, Vincent Habouzit, Nicolas De Leiris, J.-P. Vuillez, M.‐T. Leccia , et al. · 2021

Our aim was to analyse whether biomarkers extracted from baseline 18 F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior …

Impact of the COVID-19 pandemic on nuclear medicine departments in Europe Open

Ana Paula Moreira, François Jamar, Zehra Özcan, Doina Piciu, C. Als , et al. · 2021

Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments Open

Jacques Rouanet, Mercédès Quintana, Philippe Auzeloux, F. Cachin, Françoise Degoul · 2021

Cutaneous melanoma arises from proliferating melanocytes, cells specialized in the production of melanin. This property means melanin can be considered as a target for monitoring melanoma patients using nuclear imaging or targeted radionuc…

Decision Tree With Only Two Musculoskeletal Sites to Diagnose Polymyalgia Rheumatica Using [18F]FDG PET-CT Open

Anthime Flaus, Julie Amat, Nathalie Prévôt, Louis Olagne, Lucie Descamps , et al. · 2021

Introduction: The aim of this study was to find the best ordered combination of two FDG positive musculoskeletal sites with a machine learning algorithm to diagnose polymyalgia rheumatica (PMR) vs. other rheumatisms in a cohort of patients…

[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer Open

E. Jouberton, Sébastien Schmitt, Emmanuel Chautard, Aurélie Maisonial‐Besset, Marie Roy , et al. · 2020

Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues Open

Pierre Lovinfosse, Caroline Rousseau, Jean‐Yves Pierga, Francis Bouchet, Alexandre Cochet , et al. · 2019

Purpose For differentiating tumor from inflammation and normal tissues, fluorodeoxyglucose ([ 18 F]FDG) dual time point PET could be helpful. Albeit [ 18 F]FLT is more specific for tumors than [ 18 F]FDG; we explored the role of dual time …

Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance Open

Mohamad Yakhni, Arnaud Briat, Abderrahim El Guerrab, Ludivine Furtado, Fabrice Kwiatkowski , et al. · 2019

International audience

Good clinical practice recommendations for the use of PET/CT in oncology Open

Pierre‐Yves Salaün, Ronan Abgral, O. Malard, S. Querellou, Gilles Quéré , et al. · 2019

Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer Open

Christophe Bouvet, B. Barrès, Fabrice Kwiatkowski, Marie Batisse‐Lignier, Meryem Chafai El Alaoui , et al. · 2019

Introduction: Loco regional persistence or recurrence of differentiated thyroid cancer (DTC) is frequent despite initial thyroidectomy and radioactive iodine therapy (RAI). The aim of this study was to analyze the impact of a comple…

Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients Open

A. Kelly, B. Barrès, Fabrice Kwiatkowski, Marie Batisse‐Lignier, Bernadette Aubert , et al. · 2019

Initial ATA high-risk classification, age over 55 years old and pre-ablation sTg ≥30 μg/l are the main negative factors that influence the ten-year survival in DTC. We suggest three categories of overall survival rates. Patients older than…

Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers Open

B. Barrès, A. Kelly, Fabrice Kwiatkowski, Marie Batisse‐Lignier, Geneviève Fouilhoux , et al. · 2019

Context Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help t…

Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Open

Mohamad Yakhni, Arnaud Briat, Abderrahim El Guerrab, Ludivine Furtado, Fabrice Kwiatkowski , et al. · 2019

Triple negative breast cancers (TNBC) without BRCA1/2 gene mutation or BRCAness are nowadays the breast malignancies most difficult to treat. Improvement of their treatment, for all phases of the disease, is an important unmet medic…

Radium 223 dichloride for prostate cancer treatment Open

Emmanuel Deshayes, M. Roumiguié, Constance Thibault, Philippe Beuzeboc, F. Cachin , et al. · 2017

Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo^®) is a radioactive isotope that induces irreversible …

F. Cachin YOU? Author Swipe